Ovarian Epithelial Tumor

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (2) HC (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
FDA (2) HC (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
FDA (2) HC (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
FDA (2) HC (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
FDA (1) HC (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1) HC (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1) HC (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1) HC (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine
FDA (1)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab